No connection

Search Results

FONR vs LLY

FONR
FONAR Corporation
NEUTRAL
Price
$18.61
Market Cap
$117.3M
Sector
Healthcare
AI Confidence
75%
LLY
Eli Lilly and Company
NEUTRAL
Price
$958.65
Market Cap
$858.01B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
FONR
16.18
LLY
41.7
Forward P/E
FONR
--
LLY
22.78
P/B Ratio
FONR
0.69
LLY
32.33
P/S Ratio
FONR
1.11
LLY
13.16
EV/EBITDA
FONR
6.29
LLY
27.08

Profitability

Gross Margin
FONR
40.8%
LLY
83.04%
Operating Margin
FONR
11.74%
LLY
44.9%
Profit Margin
FONR
7.12%
LLY
31.67%
ROE
FONR
6.01%
LLY
101.16%
ROA
FONR
3.16%
LLY
19.41%

Growth

Revenue Growth
FONR
2.4%
LLY
42.6%
Earnings Growth
FONR
1.1%
LLY
51.4%

Financial Health

Debt/Equity
FONR
0.24
LLY
1.65
Current Ratio
FONR
10.0
LLY
1.58
Quick Ratio
FONR
9.66
LLY
0.78

Dividends

Dividend Yield
FONR
--
LLY
0.68%
Payout Ratio
FONR
0.0%
LLY
26.14%

AI Verdict

FONR NEUTRAL

FONR presents as a classic value play with a stable Piotroski F-Score of 4/9 and a current price ($18.61) trading significantly below its Graham Number ($26.43). The company maintains an exceptionally strong balance sheet with a Current Ratio of 10.00 and very low debt (D/E 0.24), providing a massive safety cushion. However, this financial stability is offset by stagnant growth metrics, with YoY earnings growth of only 1.10%, and a bearish technical trend (10/100). Ultimately, the stock appears to be a low-risk, low-reward 'value trap' unless a growth catalyst emerges.

Strengths
Exceptional liquidity with a Current Ratio of 10.00
Very low leverage (Debt/Equity of 0.24)
Trading at a discount to book value (P/B 0.69)
Risks
Stagnant growth (Revenue growth of only 2.40% YoY)
Bearish technical trend (10/100 score)
Low insider sentiment (40/100)
LLY NEUTRAL

LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.

Strengths
Strong profitability (31.7% margin)
Strong revenue growth of 42.6%
Strong ROE of 101.2%
Risks
High valuation with P/E of 41.7
Premium vs Graham Number ($123.85)
Weak financial trend (Piotroski F-Score: 3/9)

Compare Another Pair

FONR vs LLY: Head-to-Head Comparison

This page compares FONAR Corporation (FONR) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile